H-Index
75
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
17%
Acceptance
Rate
call: +1.631.4701.9640
Mon-Fri 10 am - 2 pm EST

Logo



eISSN: 1643-3750


Published: 2020-02-16

Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer

Li Wei, Jie Chen, Jingyun Wen, Donghao Wu, Xiaokun Ma, Zhanhong Chen, Jianglong Huang

(Department of Medical Oncology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China (mainland))

Med Sci Monit 2020; 26:e919031

DOI: 10.12659/MSM.919031


BACKGROUND: The aim of this study was to perform an accurate exploration on the efficacy of oxaliplatin/5-fluorouracil/capecitabine-cetuximab combination therapy and its effects on K-Ras mutations in advanced colorectal cancer.
MATERIAL AND METHODS: Among 96 patients who suffered metastatic colorectal cancer without mutated K-Ras, 41 patients who were receiving treatment with oxaliplatin/5-fluorouracil/capecitabine and administered cetuximab as the initial treatment comprised the observation group; the remaining 55 patients receiving cetuximab as an alternative treatment comprised the control group.
RESULTS: The observation group experienced significantly higher objective response rates (ORRs), and disease control rates (DCRs), than the control group (P<0.05 for both). The median progression-free survival (PFS) rates of the observation group and the control groups were 11.2 months (95% confidence interval [CI]: 10.1-12.3 months) and 7.4 months (95% CI: 6.6-8.2 months). The median overall survival (OS) rates were 16.8 months (95% CI: 15.2-18.4 months) and 12.4 months (95% CI: 11.6-13.2 months), respectively. The observation group had significantly longer PFS and OS in comparison to the control group (P<0.05). The patients who underwent cetuximab treatment for ≥10 months had a slightly higher rate of K-Ras mutations than those treated with cetuximab for <10 months (9.1% versus 7.3%).
CONCLUSIONS: Oxaliplatin/5-fluorouracil/capecitabine plus cetuximab exhibited better efficacy as initial treatment than the alternative treatment; it was also highly safe. Unfortunately, some patients might develop K-Ras mutations after long duration of cetuximab treatment, suggesting that K-Ras mutations are correlated with tumor progression and depend on the duration or dose of cetuximab treatment.

Keywords: Colorectal Neoplasms, Drug Combinations, Treatment Outcome



Related Articles (0)

Coming Soon...

Published: 2020-02-16

Association Between Cystatin C and Cardiac Function and Long-Term Prognosis in Patients with Chronic Hear...


Xilin Wu, Ge Xu, Shiming Zhang

Med Sci Monit 2020; 26:e919422

DOI: 10.12659/MSM.919422

Published: 2020-02-16

Effects of Hetiao Jianpi Decoction on Intestinal Injury and Repair in Rats with Antibiotic-Associated Dia...


Xiaoya Li, Yueying Wu, Zhenyuan Xu, Jing Chen, Yuqing Li, Haijing Xing, Xiaomei Zhang, Jiali Yuan

Med Sci Monit 2020; 26:e921745

DOI: 10.12659/MSM.921745